Comparison of electrodiagnostic findings in patients with post-COVID-19 and non-COVID-19 Guillain-Barre syndrome

Yıl 2022, , 539 - 543, 15.03.2022

Recep Yevgi , Nuray Bilge

https://doi.org/10.32322/jhsm.1054313

Öz

Aim: The aim of this study is to compare the electrophysiological features of patients with Guillain-Barré syndrome (GBS) after Coronavirus disease–2019 (COVID-19) and the electrophysiological features of patients with non-COVID-19 GBS and to determine whether there is a difference between these two groups in terms of nerve dysfunction.
Material and Method: The electromyography results of the patients followed up with the diagnosis of GBS between December 2019 and December 2021 in the Neurology Department of Atatürk University Faculty of Medicine were retrospectively analyzed. Patients with a history of COVID-19 in the 6-week period before the occurrence of GBS were considered as the post-COVID-19 GBS group. Patients who did not have a history of COVID-19 but developed GBS were considered the non-COVID-19 GBS group. Electrodiagnostic findings of the patients were compared between two groups.
Results: Motor compound muscle action potential (CMAP) amplitude of the median nerve was detected as 1.94±1.43 mV in post-COVID-19 GBS group and 5.94±4.6 mV in non-COVID-19 GBS group (p<0.05). On the other hand, motor CMAP amplitude of ulnar nerve was 2.82±1.61 mV in post-COVID-19 GBS group and 6.28±4.2 mV in non-COVID-19 GBS group (p<0.05). Motor CMAP amplitude of the tibial nerve was detected as 1.3±1.06 mV in post-COVID-19 GBS group and 3.5±3.6 mV in non- COVID-19 GBS group (p<0.05). No significant difference was observed between the two groups in terms of other parameters.
Conclusion: Motor CMAP amplitudes of median, ulnar and tibial nerves were significantly low in post-COVID-19 GBS group when compared with non-COVID-19 GBS group. This result may indicate that the degree of axonal involvement and related nerve dysfunction in post-COVID-19 GBS patients in the acute period is higher than in non-COVID-19 GBS patients.

Anahtar Kelimeler

Guillain Barre Syndrome, COVİD-19, EMG, CMAP, SNAP, Distal latency, conduction velocity

Kaynakça

• Portela-Sánchez S, Sánchez-Soblechero A, Melgarejo Otalora PJ, et al. Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic. Eur J Neurol 2021; 28: 3339-47.
• Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Complicaciones neurológicas por coronavirus y COVID-19. Rev Neurol 2020; 70: 311-22.
• Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological Involvement in COVID-19 and Potential Mechanisms: A Review. Neurocrit Care 2021; 34: 1062-71.
• Meppiel E, Peiffer-Smadja N, Maury A, et al. Neurologic manifestations associated with COVID-19: a multicentre registry. Clin Microbiol Infect 2021; 27: 458-66.
• Caress JB, Castoro RJ, Simmons Z, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve 2020; 62: 485-491.
• Filosto M, Cotti Piccinelli S, Gazzina S, et al. Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry 2021; 92: 751-6.
• Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2021; 268: 1133-70.
• 8.Kajumba MM, Kolls BJ, Koltai DC, Kaddumukasa M, Kaddumukasa M, Laskowitz DT. COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications. SN Compr Clin Med 2020; 1-13.
• Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol 2021; 28: 3517-29.
• Gupta A, Paliwal VK, Garg RK. Is COVID-19-related Guillain-Barré syndrome different? Brain Behav Immun 2020; 87: 177-8.
• Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27: 21-4.
• Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry 2015; 86: 115-9.
• van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007; 6: 589-94.
• Uncini A, Foresti C, Frigeni B, et al. Electrophysiological features of acute inflammatory demyelinating polyneuropathy associated with SARS-CoV-2 infection. Neurophysiol Clin 2021; 51: 183-91.
• Aladawi M, Elfil M, Abu-Esheh B, et al. Guillain Barre Syndrome as a complication of COVID-19: a systematic review. Can J Neurol Sci 2022; 49: 38-48.
• De Sanctis P, Doneddu PE, Viganò L, Selmi C, Nobile-Orazio E. Guillain-Barré syndrome associated with SARS-CoV-2 infection. A systematic review. Eur J Neurol 2020; 27: 2361-70.
• Daia C, Scheau C, Neagu G, et al. Nerve conduction study and electromyography findings in patients recovering from COVID-19 - Case report. Int J Infect Dis 2021; 103: 420-2.
• Agergaard J, Leth S, Pedersen TH, et al. Myopathic changes in patients with long-term fatigue after COVID-19. Clin Neurophysiol 2021; 132: 1974-81.